Evidence map›Paper›PMID 28834396›Full record

SynthesisESC heart failure2017

Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials.

Simona Silvetti, Alessandro Belletti, Antonella Fontana, Piero Pollesello

Open access · goldAbstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in ESC heart failure, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Highlights in heart failure.ESC heart failure · 2019
    Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Advanced heart failure: a contemporary approach.The Korean journal of internal medicine · 2023
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Repetitive levosimendan treatment in the management of advanced heart failure.European heart journal supplements : journal of the European Society of Cardiology · 2018
    Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 3 countries.

Simona SilvettiIRCCS San Raffaele Scientific Institute, Milan, Italy.
Alessandro BellettiIRCCS San Raffaele Scientific Institute, Milan, Italy.
Antonella FontanaOrion Pharma, Espoo, Finland.
Piero PolleselloOrion Pharma, Espoo, Finland.ORCID 0000-0001-6994-768X
Orion Corporation (Finland) · FIVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsIntermittent levosimendan administration has been suggested to improve survival in patients with advanced heart failure (AdHF). Quality of life is a key issue for AdHF patients and is negatively affected by frequent hospitalizations. METHODS AND

resultsCENTRAL, Google Scholar, MEDLINE/PubMed, Scopus, and the Cochrane Central Register of clinical trials (updated 15/1/2017) were searched for randomized controlled trials investigating the effect of intermittent levosimendan administration in patients with AdHF. The primary outcome was the number of patients requiring rehospitalization 3 months after the end of treatment. A total of 319 patients from six trials were included. Overall pooled analysis showed that the use of levosimendan was associated with a significant reduction in the number of rehospitalizations at 3 months: 33/207 (16%) vs. 39/113 (35%), risk ratio 0.40, 95% confidence interval 0.27-0.59, P < 0.001, I

conclusionsWithin the limitations of this meta-analysis including also studies in which endpoints were not independently adjudicated and not clearly specified, repetitive or intermittent administration of levosimendan for patients with AdHF was associated with a reduction in the rehospitalization rate at 3 months. Large, high-quality randomized controlled trials are needed to confirm this finding.

Indexed as

Randomized Controlled Trials as TopicCause of DeathDose-Response Relationship, DrugDrug Administration ScheduleGlobal HealthHeart FailureHumansHydrazonesPatient ReadmissionPyridazinesSimendanSurvival RateVasodilator AgentsHydrazonesPyridazinesSimendanVasodilator AgentsAdvanced heart failureIntermittentLevosimendanMeta-analysisRehospitalizationRepetitive

Identifiers

PMID28834396
PMCPMC5695198
OpenAlexW2732019774

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.